Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study
Background In vitro data suggested reduced neutralizing capacity of sotrovimab, a monoclonal antibody, against Omicron BA.2 subvariant. However, limited in vivo data exist regarding clinical effectiveness of sotrovimab for coronavirus disease 2019 (COVID-19) due to Omicron BA.2. Methods A multicentre, retrospective cohort study was conducted at three Canadian academic tertiary centres. Electronic medical records were reviewed for patients ≥ 18 years with mild COVID-19 (sequencing-confirmed Omicron BA.1 or BA.2) treated with sotrovimab between February 1 to April 1, 2022. Thirty-day co-primary outcomes included hospitalization due to moderate or severe COVID-19; all-cause intensive care unit (ICU) admission, and all-cause mortality. Risk differences (BA.2 minus BA.1 group) for co-primary outcomes were adjusted with propensity score matching (e.g., age, sex, vaccination, immunocompromised status). Results Eighty-five patients were included (15 BA.2, 70 BA.1) with similar baseline characteristics between groups. Adjusted risk differences were non-statistically significant between groups for 30-day hospitalization (− 14.3%; 95% confidence interval (CI): − 32.6 to 4.0%), ICU admission (− 7.1%; 95%CI: − 20.6 to 6.3%), and mortality (− 7.1%; 95%CI: − 20.6 to 6.3%). Conclusions No differences were demonstrated in hospitalization, ICU admission, or mortality rates within 30 days between sotrovimab-treated patients with BA.1 versus BA.2 infection. More real-world data may be helpful to properly assess sotrovimab’s effectiveness against infections due to specific emerging COVID-19 variants..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
BMC Research Notes - 17(2024), 1 vom: 24. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lo, Carson K. L. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s13104-024-06695-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054511038 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054511038 | ||
| 003 | DE-627 | ||
| 005 | 20240125064801.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13104-024-06695-x |2 doi | |
| 035 | |a (DE-627)SPR054511038 | ||
| 035 | |a (SPR)s13104-024-06695-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lo, Carson K. L. |e verfasserin |0 (orcid)0000-0002-1620-2868 |4 aut | |
| 245 | 1 | 0 | |a Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Background In vitro data suggested reduced neutralizing capacity of sotrovimab, a monoclonal antibody, against Omicron BA.2 subvariant. However, limited in vivo data exist regarding clinical effectiveness of sotrovimab for coronavirus disease 2019 (COVID-19) due to Omicron BA.2. Methods A multicentre, retrospective cohort study was conducted at three Canadian academic tertiary centres. Electronic medical records were reviewed for patients ≥ 18 years with mild COVID-19 (sequencing-confirmed Omicron BA.1 or BA.2) treated with sotrovimab between February 1 to April 1, 2022. Thirty-day co-primary outcomes included hospitalization due to moderate or severe COVID-19; all-cause intensive care unit (ICU) admission, and all-cause mortality. Risk differences (BA.2 minus BA.1 group) for co-primary outcomes were adjusted with propensity score matching (e.g., age, sex, vaccination, immunocompromised status). Results Eighty-five patients were included (15 BA.2, 70 BA.1) with similar baseline characteristics between groups. Adjusted risk differences were non-statistically significant between groups for 30-day hospitalization (− 14.3%; 95% confidence interval (CI): − 32.6 to 4.0%), ICU admission (− 7.1%; 95%CI: − 20.6 to 6.3%), and mortality (− 7.1%; 95%CI: − 20.6 to 6.3%). Conclusions No differences were demonstrated in hospitalization, ICU admission, or mortality rates within 30 days between sotrovimab-treated patients with BA.1 versus BA.2 infection. More real-world data may be helpful to properly assess sotrovimab’s effectiveness against infections due to specific emerging COVID-19 variants. | ||
| 650 | 4 | |a Sotrovimab |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 drug treatment |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Omicron |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a BA.2 subvariant |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Antibodies, Monoclonal |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Lo, Calvin K. F. |0 (orcid)0000-0003-3664-736X |4 aut | |
| 700 | 1 | |a Komorowski, Adam S. |0 (orcid)0000-0003-2101-7701 |4 aut | |
| 700 | 1 | |a Leung, Victor |0 (orcid)0000-0001-9756-4416 |4 aut | |
| 700 | 1 | |a Matic, Nancy |0 (orcid)0000-0002-4158-6955 |4 aut | |
| 700 | 1 | |a McKenna, Susan |0 (orcid)0009-0007-8035-4819 |4 aut | |
| 700 | 1 | |a Perez-Patrigeon, Santiago |0 (orcid)0000-0002-5912-453X |4 aut | |
| 700 | 1 | |a Sheth, Prameet M. |0 (orcid)0000-0003-0029-7345 |4 aut | |
| 700 | 1 | |a Lowe, Christopher F. |0 (orcid)0000-0001-9320-4499 |4 aut | |
| 700 | 1 | |a Chagla, Zain |0 (orcid)0000-0002-3619-7031 |4 aut | |
| 700 | 1 | |a Bai, Anthony D. |0 (orcid)0000-0003-0448-9934 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC Research Notes |d London, 2008 |g 17(2024), 1 vom: 24. Jan. |w (DE-627)SPR030264820 |w (DE-600)2413336-X |x 1756-0500 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2024 |g number:1 |g day:24 |g month:01 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13104-024-06695-x |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2024 |e 1 |b 24 |c 01 | ||